Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) saw a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 49,500 shares, a decrease of 71.7% from the November 15th total of 175,000 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily volume of 172,900 shares, the days-to-cover ratio is presently 0.3 days.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. RODMAN&RENSHAW raised Adial Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Adial Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $8.00 price target for the company.

Adial Pharmaceuticals Price Performance

Shares of ADIL stock traded down $0.06 during trading hours on Wednesday, hitting $1.13. 95,937 shares of the company’s stock traded hands, compared to its average volume of 2,502,693. Adial Pharmaceuticals has a 12 month low of $0.77 and a 12 month high of $4.17. The stock’s 50 day simple moving average is $1.03 and its 200 day simple moving average is $1.08.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.